ADAM6 and acute lymphoblastic leukemia: Thus, overall, ADAM6 can be regarded as a relatively good diagnostic biomarker in acute leukemia patients with a potential prognostic implication in ALL which requires further investigations in larger cohorts to be fully elucidated.